Monoamine transporters: vulnerable and vital doorkeepers.
Monoamine transporters: vulnerable and vital doorkeepers.
复制标题
DOI：
10.1016/b978-0-12-385506-0.00001-6
复制
发表时间：
2011
影响因子：
--
通讯作者：
Caine, S. Barak
中科院分区：
文献类型：
--
作者：
Lin, Zhicheng;Canales, Juan J.;Bjoergvinsson, Throestur;Thomsen, Morgane;Qu, Hong;Liu, Qing-Rong;Torres, Gonzalo E.;Caine, S. Barak
在过去的几十年里，多巴胺、5-羟色胺和去甲肾上腺素的转运蛋白已被经验性地用作几种精神疾病的药物靶点。这些蛋白质靶向药物仅对转运蛋白相关脑疾病患者亚群有效。自20世纪90年代初cDNA克隆以来，对这些转运蛋白的分子研究揭示了它们的构效关系（SAR）、神经药理学、细胞生物学、生物化学、药物遗传学以及与编码这些转运蛋白的人类基因相关的疾病的信息。这些新的信息创造了一个独特的机会，开发转运蛋白特异性药物的基础上SAR，mRNA，DNA，也许转运蛋白贩运的监管，高度相关的疾病，包括药物滥用，抑郁症，精神分裂症和帕金森氏病的名单。
Transporters of dopamine, serotonin and norepinephrine have been empirically used as medication targets for several mental illnesses for the last decades. These protein-targeted medications are effective only for subpopulations of patients with transporter-related brain disorders. Since the cDNA clonings in early 1990’s, molecular studies of these transporters have revealed a wealth of information about the transporters’ structure activity relationship (SAR), neuropharmacology, cell biology, biochemistry, pharmacogenetics and the diseases related to the human genes encoding these transporters among related regulators. Such new information creates a unique opportunity to develop transporter-specific medications based on SAR, mRNA, DNA and perhaps transporter trafficking regulation, for a list of highly relevant diseases including substance abuse, depression, schizophrenia and Parkinson’s disease.